Chief Executive Officer
Mark joined Quotient as Chief Executive Officer in August 2005. Mark has over 20 years’ experience in the pharmaceutical and biotech industry and has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies. Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the U.K. with Incyte Pharmaceuticals to head up European Business
Gordon Cameron OBE
Chief Financial Officer
Gordon joined Quotient in 2013, having served as CFO of its previous owners, Quotient Bioresearch group, for six years. Gordon is responsible for all financial matters, including financial reporting, liaising with Quotient’s investors and lenders and leading fund-raisings and M&A activities. Gordon has over 20 years’ experience in the pharmaceutical and biotech industry, in both private equity-backed and public companies. He spent 11 years as CFO and then CEO of Acambis plc, a FTSE-350 vaccines development company. He headed up Acambis’ U.S. operations for five years, delivering a $500 smallpox vaccine counter-bioterrorism contract for the U.S. Government. Prior to that Gordon spent six years as an investment banker, primarily with N M Rothschild, where he advised clients on a variety of corporate finance transactions. He qualified as a Chartered Accountant with Ernst & Young. In 2004, Gordon was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry in the U.S.
Mike is an Executive Partner and Founder of GHO Capital. He has 30 years of operating and management experience, most recently at Quintiles as an Executive Vice President. In this role, he was responsible for Quintiles’ global operations in Health Engagement and Communications, Legal and Risk Management, Real Estate and Facilities, Human Resources as well as Security. He was also the Chairman of the company’s European, Middle East, Africa and Latin American management board, in which he was accountable for the organic and inorganic growth strategies of the regions. Mike joined Quintiles in July of 2003 following 10 years at Charles Schwab Corp., where he was a Senior Vice President in the company’s global retail and internet organizations. Mike sits on the boards of HUYA Bioscience International and is Chairman of the Multiple Myeloma Research Foundation. He holds a bachelor’s degree in Behavioral Sciences from The Ohio State University.
Alan is an Executive Partner and Founder of GHO Capital. He has been a private equity investor for 30 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He was Chair of the BVCA for 2016 – 2017 and has chaired its Responsible Investment Advisory Board.
Dr Thomis has 40 years of experience in the clinical and commercial development of new medicines, including 20 years at executive level with Quintiles where he was most recently Chairman of the American Management Board. From 1997-2010, as President of European Clinical Development and then as President of Global Clinical Development, Dr Thomis was responsible for creating a global division of 12,000 people across 59 countries. Dr Thomis joined Quintiles in 1997 following 20 years at Bristol-Myers Squibb, where he held senior positions in Clinical Research and Medical Development across Europe and the U.S. Dr Thomis is a partner in OxOnc and and has previously held board positions at Idis Pharma (2013-15), PDP Courier Services (2012-13) in addition to America (2010-2012) and Quintiles EMEA (2003-2005). Dr Thomis currently sits on the board of Cesca Therapeutics, a Nasdaq traded company, and is a Senior Advisor to GHO Capital.